Search
Now showing items 1-4 of 4
Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories
(Wiley, 2017-01-20)
Over the past few years, treatment options for chronic hepatitis C virus (HCV) infection have evolved dramatically. The current approved interferon-free direct-acting antiviral (DAA) regimens have been shown to be safe and ...
Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
(Wiley, 2019-01-13)
Abstract
Background & Aims: Data from Europe and North America have been published re‐
garding the risk of developing hepatocellular carcinoma (HCC) after treatment with
direct antiviral agents (DAA). We proposed to ...
'Real-life' experience with direct-acting antiviral agents for HCV after kidney transplant
(Elsevier, 2021-11)
Abstract
Introductions and objectives: The introduction of direct-acting antiviral (DAA) agents promises to change dramatically the management of hepatitis C in kidney transplant recipients, a patient group where the ...
Simplified treatment of hepatitis C: another strategy to overcome the barriers to its elimination
(Medicina Buenos Aires, 2021-01)
Abstract in English, Spanish
The clinical management of hepatitis C virus (HCV) infection presents several challenges today. WHO's goal is to eliminate it by 2030. It is an ambitious goal and difficult to meet given the ...